Current Clinical Practice of Precision Medicine Using Comprehensive Genomic Profiling Tests in Biliary Tract Cancer in Japan

Kanai, Masashi

doi:10.3390/curroncol29100573

Cited by 5 publications

(5 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three types of CGP tests were approved before (or during) the study period in Japan: a tumor/normal paired CGP test (OncoGuide™ NCC Oncopanel System), 15 a tumor‐only CGP test (FoundationOne®CDx), and a liquid biopsy CGP test (FoundationOne®Liquid CDx) 16 …”

Section: Methodsmentioning

confidence: 99%

Patient survey on cancer genomic medicine in Japan under the national health insurance system

Kage,

Akiyama,

Chang

et al. 2024

Cancer Science

View full text Add to dashboard Cite

In Japan, comprehensive genomic profiling (CGP) tests have been reimbursed under the national health care system for solid cancer patients who have finished standard treatment. More than 50,000 patients have taken the test since June 2019. We performed a nation‐wide questionnaire survey between March 2021 and July 2022. Questionnaires were sent to 80 designated Cancer Genomic Medicine Hospitals. Of the 933 responses received, 370 (39.7%) were web based and 563 (60.3%) were paper based. Most patients (784, 84%) first learned about CGP tests from healthcare professionals, and 775 (83.1%) gave informed consent to their treating physician. At the time of informed consent, they were most worried about test results not leading to novel treatment (536, 57.4%). On a scale of 0–10, 702 respondents (75.2%) felt that the explanations of the test result were easy to understand (7 or higher). Ninety‐one patients (9.8%) started their recommended treatment. Many patients could not receive recommended treatment because no approved drugs or clinical trials were available (102/177, 57.6%). Ninety‐eight patients (10.5%) did not wish their findings to be disclosed. Overall satisfaction with the CGP test process was high, with 602 respondents (64.5%) giving a score of 7–10. The major reason for choosing 0–6 was that the CGP test result did not lead to new treatment (217/277, 78.3%). In conclusion, satisfaction with the CGP test process was high. Patients and family members need better access to information. More patients need to be treated with genomically matched therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Patient survey on cancer genomic medicine in Japan under the national health insurance system

Kage,

Akiyama,

Chang

et al. 2024

Cancer Science

View full text Add to dashboard Cite

show abstract

“…1) [84][85][86][87][88][89][90][91][92][93][94][95]. The National Cancer Center Network guidelines list eight druggable markers in biliary tract cancer (NTRK fusion, MSI-H, TMB-H, BRAF, V600E, FGFR2 fusions/rearrangement, IDH1 mutations, RET fusion, and HER2 overexpression) and their corresponding therapeutic agents [96].…”

Section: Genomic Analysis Of Biliary Tract Cancers Using Eus-fna/fnb ...mentioning

confidence: 99%

Is genomic analysis possible in a tissue acquired via endoscopic ultrasound-guided fine-needle biopsy in cholangiocarcinoma?

Lee,

Han

2024

Clin Endosc

View full text Add to dashboard Cite

“…1 ) [ 84 – 95 ]. The National Cancer Center Network guidelines list eight druggable markers in biliary tract cancer ( NTRK fusion, MSI-H , TMB-H , BRAF , V600E , FGFR2 fusions/rearrangement, IDH1 mutations, RET fusion, and HER2 overexpression) and their corresponding therapeutic agents [ 96 ].…”

Section: Genomic Analysis Of Biliary Tract Cancers Using Eus-fna/fnb ...mentioning

confidence: 99%

Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary–pancreatic cancers

Ozono,

Kawakami,

Uchiyama

et al. 2023

J Gastroenterol

View full text Add to dashboard Cite

Comprehensive genomic profiling based on next-generation sequencing has recently been used to provide precision medicine for various advanced cancers. Endoscopic ultrasound (EUS)-guided fine-needle aspiration (EUS-FNA) and EUS-guided fine-needle biopsy (EUS-FNB) play essential roles in the diagnosis of abdominal masses, mainly pancreatic cancers. In recent years, CGP analysis using EUS-FNA/FNB specimens for hepatobiliary–pancreatic cancers has increased; however, the success rate of CGP analysis is not clinically satisfactory, and many issues need to be resolved to improve the success rate of CGP analysis. In this article, we review the transition from EUS-FNA to FNB, compare each test, and discuss the current status and issues in genomic analysis of hepatobiliary–pancreatic cancers using EUS-FNA/FNB specimens.

show abstract

Current Clinical Practice of Precision Medicine Using Comprehensive Genomic Profiling Tests in Biliary Tract Cancer in Japan

Cited by 5 publications

References 77 publications

Patient survey on cancer genomic medicine in Japan under the national health insurance system

Patient survey on cancer genomic medicine in Japan under the national health insurance system

Is genomic analysis possible in a tissue acquired via endoscopic ultrasound-guided fine-needle biopsy in cholangiocarcinoma?

Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary–pancreatic cancers

Contact Info

Product

Resources

About